By Julie Zeveloff (July 23, 2008, 12:00 AM EDT) -- As a litigator with regulatory experience, Dan Troy brings a unique vantage point to his newest role as general counsel and senior vice president at GlaxoSmithKline, where he is set to face a U.S. Department of Justice probe of the company's antidepressant Paxil and charges that the company delayed a generic release to keep profits high.
Troy, who is currently a partner in Sidley Austin LLP's life sciences practice, is set to join GSK on Sept. 2, the company announced Tuesday.
The pharmaceutical giant is embroiled in investigations and legal conflicts over several of its products, including the antidepressant Paxil. The...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!